JP2023529065A - Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物 - Google Patents

Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物 Download PDF

Info

Publication number
JP2023529065A
JP2023529065A JP2022568723A JP2022568723A JP2023529065A JP 2023529065 A JP2023529065 A JP 2023529065A JP 2022568723 A JP2022568723 A JP 2022568723A JP 2022568723 A JP2022568723 A JP 2022568723A JP 2023529065 A JP2023529065 A JP 2023529065A
Authority
JP
Japan
Prior art keywords
nanoparticles
hpv
poly
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529065A5 (cg-RX-API-DMAC7.html
Inventor
アンゲーリカ リーマー，
アルミン キューベルベック，
アグニエシュカ グラボウスカ，
ゼバスティアン クルーゼ，
エーファ ファイト，
エレン ユングラース，
Original Assignee
ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー
ドイチェス クレープスフォアシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒテス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー, ドイチェス クレープスフォアシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒテス filed Critical ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー
Publication of JP2023529065A publication Critical patent/JP2023529065A/ja
Publication of JP2023529065A5 publication Critical patent/JP2023529065A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022568723A 2020-05-12 2021-05-12 Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物 Pending JP2023529065A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20174156.8A EP3909612A1 (en) 2020-05-12 2020-05-12 Composition of nanoparticles
EP20174156.8 2020-05-12
EP20196027.5 2020-09-14
EP20196027.5A EP3909614A1 (en) 2020-05-12 2020-09-14 Composition of nanoparticles as carrier for hpv-derived immunogenic fragments
PCT/EP2021/062748 WO2021229014A1 (en) 2020-05-12 2021-05-12 Composition of nanoparticles as carrier for hpv-derived immunogenic fragments

Publications (2)

Publication Number Publication Date
JP2023529065A true JP2023529065A (ja) 2023-07-07
JP2023529065A5 JP2023529065A5 (cg-RX-API-DMAC7.html) 2024-05-22

Family

ID=70682623

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022568723A Pending JP2023529065A (ja) 2020-05-12 2021-05-12 Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物
JP2022568554A Pending JP2023524874A (ja) 2020-05-12 2021-05-12 ナノ粒子の組成物
JP2022568724A Pending JP2023529066A (ja) 2020-05-12 2021-05-12 アジュバント／抗原の担体系としてのナノ粒子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022568554A Pending JP2023524874A (ja) 2020-05-12 2021-05-12 ナノ粒子の組成物
JP2022568724A Pending JP2023529066A (ja) 2020-05-12 2021-05-12 アジュバント／抗原の担体系としてのナノ粒子

Country Status (4)

Country Link
US (4) US20240197909A1 (cg-RX-API-DMAC7.html)
EP (6) EP3909612A1 (cg-RX-API-DMAC7.html)
JP (3) JP2023529065A (cg-RX-API-DMAC7.html)
WO (3) WO2021229015A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529066A (ja) * 2020-05-12 2023-07-07 ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー アジュバント／抗原の担体系としてのナノ粒子

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113274492B (zh) * 2021-05-21 2022-06-17 大连理工大学 一种基于羟基氧化铝纳米羧基改性的复合疫苗佐剂的制备方法
EP4547258A4 (en) * 2022-06-28 2026-08-05 Transcode Therapeutics Inc Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy
EP4551242A4 (en) * 2022-07-08 2026-06-24 Mark C Poznansky VACCINE CONTAINING A PROTEIN IMMUNE ADJUVANT
EP4673170A1 (en) * 2023-03-02 2026-01-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes
CN120857941A (zh) * 2023-03-02 2025-10-28 德国癌症研究公共权益基金会 经验证的hpv16衍生的刺激肽
EP4673166A1 (en) * 2023-03-02 2026-01-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Therapeutic hpv vaccines based on validated target epitopes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
WO2015086354A2 (en) * 2013-12-12 2015-06-18 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
WO2017223085A2 (en) * 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2018085751A1 (en) * 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
WO2019097226A1 (en) * 2017-11-14 2019-05-23 N4 Pharma Uk Limited Particulate material production process

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616133A1 (de) 1985-09-25 1987-11-19 Merck Patent Gmbh Kugelfoermige sio(pfeil abwaerts)2(pfeil abwaerts)-partikel
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2148259T3 (es) 1993-09-22 2000-10-16 Hoechst Ag Pro-profarmacos, su produccion y uso.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
DE19912502A1 (de) * 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
DE102004011110A1 (de) 2004-03-08 2005-09-22 Merck Patent Gmbh Verfahren zur Herstellung monodisperser SiO2-Partikel
US20060088599A1 (en) * 2004-08-02 2006-04-27 Prasad Paras N Amino functionalized ORMOSIL nanoparticles as delivery vehicles
ES2625905T3 (es) 2004-10-01 2017-07-20 Midatech Ltd. Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores
WO2006063252A2 (en) 2004-12-09 2006-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
CN101160048A (zh) * 2004-12-30 2008-04-09 哈达斯特医学研究服务与开发有限公司 形成非析出性持续抗微生物聚合组合物的抗微生物纳米颗粒添加剂
WO2007031734A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
EP1764107A1 (en) 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン ５’リン酸オリゴヌクレオチドの構造および使用
FR2908305B1 (fr) 2006-11-10 2009-02-27 Oreal Procede de deformation permanente des fibres keratiniques comprenant une etape d'application d'une composition de rincage intermediaire comprenant un sel de cation metallique monovalent ou un sel d'ammonium et un acide organique
JP5448369B2 (ja) * 2008-05-15 2014-03-19 古河電気工業株式会社 粒子表面にアミノ基を有するシリカ粒子の製造方法、粒子表面にアミノ基を有するシリカ粒子、及びそれを用いた複合粒子
DK2518150T3 (en) 2008-05-21 2015-12-07 Univ Bonn 5'Trip phosphate triphosphate oligonucleotide and uses thereof
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
DE102008033175A1 (de) 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
EP3263707A1 (en) 2009-03-17 2018-01-03 Rheinische Friedrich-Wilhelms-Universität Bonn Tlr8 ligand and uses thereof
ES2366841B1 (es) * 2010-04-06 2013-01-24 Consejo Superior De Investigaciones Cientificas (Csic) (45%) Nanoparticulas de silice para difusion intracelular de agentes bioactivos poco solubles
CN103002922B (zh) 2010-06-10 2015-11-25 Mida科技有限公司 携带肽的纳米颗粒
BR112014005362A2 (pt) 2011-09-07 2017-06-13 Immunotope Inc vacinas de tumor com nanopartículas
JP6077544B2 (ja) 2011-09-07 2017-02-08 ミダテック リミテッド ナノ粒子−ペプチド組成物
MA39909B1 (fr) 2014-04-25 2019-05-31 Pf Medicament Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
WO2016013751A1 (ko) * 2014-07-22 2016-01-28 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
EP3370741B1 (en) * 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
PT3319587T (pt) * 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
WO2019028387A1 (en) * 2017-08-03 2019-02-07 Rita Elena Serda LIPOSOMAL COATED NANOPARTICLES FOR IMMUNOTHERAPY APPLICATIONS
US20210196838A1 (en) * 2018-08-24 2021-07-01 Mirexus Biotechnologies Inc. Compounds and compositions for potentiation of tlr agonists
EP3909612A1 (en) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
WO2015086354A2 (en) * 2013-12-12 2015-06-18 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
WO2017223085A2 (en) * 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2018085751A1 (en) * 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
WO2019097226A1 (en) * 2017-11-14 2019-05-23 N4 Pharma Uk Limited Particulate material production process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 9, no. 2, JPN6025027036, 2014, pages 207 - 215, ISSN: 0005825796 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529066A (ja) * 2020-05-12 2023-07-07 ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー アジュバント／抗原の担体系としてのナノ粒子

Also Published As

Publication number Publication date
EP4149562A1 (en) 2023-03-22
EP4149560A1 (en) 2023-03-22
US20230272014A1 (en) 2023-08-31
US20260000754A1 (en) 2026-01-01
EP4149561A1 (en) 2023-03-22
US20230181727A1 (en) 2023-06-15
US20240197909A1 (en) 2024-06-20
EP3909612A1 (en) 2021-11-17
JP2023529066A (ja) 2023-07-07
JP2023524874A (ja) 2023-06-13
WO2021229014A1 (en) 2021-11-18
WO2021229015A1 (en) 2021-11-18
EP3909613A1 (en) 2021-11-17
WO2021229020A1 (en) 2021-11-18
EP3909614A1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
US20230272014A1 (en) Composition of nanoparticles as carrier for hpv-derived immunogenic fragments
EP2211899B1 (en) Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
Lin et al. Therapeutic hpv DNA vaccines
JP6862369B2 (ja) 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
Tahamtan et al. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems
Hou et al. Flower-like mesoporous silica nanoparticles as an antigen delivery platform to promote systemic immune response
CA3005251A1 (en) Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP6797022B2 (ja) 酵母細胞壁粒子を用いたワクチン送達系
CN115103687A (zh) Hpv疫苗
CA2694735A1 (en) Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action
US20240131140A1 (en) Hpv vaccine manufacture
JP2022036961A (ja) 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
CA2597865A1 (en) Compositions for therapeutic treatment of hpv related conditions and diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240513

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260626